# S1300: Pemetrexed Disodium With or Without Crizotinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer That Has Progressed After Crizotinib

> **NCT02134912** · PHASE2 · TERMINATED · sponsor: **SWOG Cancer Research Network** · enrollment: 1 (actual)

## Conditions studied

- Adenocarcinoma of the Lung
- Large Cell Lung Cancer
- Recurrent Non-small Cell Lung Cancer
- Stage IV Non-small Cell Lung Cancer

## Interventions

- **DRUG:** crizotinib
- **DRUG:** pemetrexed disodium
- **OTHER:** laboratory biomarker analysis
- **OTHER:** pharmacological study

## Key facts

- **NCT ID:** NCT02134912
- **Lead sponsor:** SWOG Cancer Research Network
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-08
- **Primary completion:** 2016-09
- **Final completion:** 2016-09
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** science has moved forward and there is no intent to complete the study
- **Last updated:** 2020-02-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02134912

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02134912, "S1300: Pemetrexed Disodium With or Without Crizotinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer That Has Progressed After Crizotinib". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT02134912. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*